APEPTICO is a biotechnology company focused on developing peptide-based therapeutics, particularly its investigational compound solnatide (AP301), which is designed to treat Acute Respiratory Distress Syndrome (ARDS) and pulmonary permeability edema. Solnatide is a synthetically manufactured peptide that has shown clinical proof-of-concept in various studies, including a Phase II trial for patients suffering from pneumonia, sepsis, and severe COVID-19. The company emphasizes the potential of solnatide to restore barrier function in endothelial cells and mitigate inflammatory responses, which are critical in managing conditions associated with severe pulmonary dysfunction.

The technology behind APEPTICO's products is rooted in its proprietary PEPBASE™ discovery platform, which focuses on discrete peptide structures derived from validated pharmacodynamic active domains of known proteins. This approach allows APEPTICO to circumvent the limitations associated with larger recombinant proteins, such as high development costs and risks of contamination. By utilizing advanced chemical synthesis for peptide production, APEPTICO aims to reduce the time to clinical trials and overall research and development expenses while ensuring safety and efficacy in its therapeutic offerings.

Austria

APEPTICO is a privately-held biotechnology company based in Austria, developing peptide-based products targeting chronic and life-threatening diseases. The peptide molecules correspond to validated, pharmacodynamic active structures and domains of well-known proteins and biopharmaceuticals. By concentrating on synthetically produced protein structures APEPTICO avoids general risks associated with gene- and cell-technologies. APEPTICO makes use of its technology platforms PEPBASE(TM) and PEPSCREEN(TM) to significantly reduce cost and to shorten time to market.

APEPTICO

Company Details